Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PMGC HoldingsELAB -0.34%8 EV-to-EBIT is 0.30 as of Jul. 30, 2026, which is 27% below its 10-year median of 0.41. GuruFocus rates ELAB with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 384 Biotechnology companies, PMGC Holdings ranks better than 88.02% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
PMGC Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was $4.47 Mil.
PMGC Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMGC Holdings EV-to-EBIT Related Terms
PMGC Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for PMGC Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PMGC Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PMGC Holdings EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PMGC Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where PMGC Holdings's EV-to-EBIT falls into.
PMGC Holdings's current Enterprise Value is $-3.15 Mil.
PMGC Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMGC Holdings (ELAB) has a EV-to-EBIT of 0.30 as of Jul. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PMGC Holdings and its competitors. This is 27% below median its historical median of 0.41. Over the past decade, PMGC Holdings' EV-to-EBIT has ranged from 0.07 to 0.65. According to the industry distribution chart, PMGC Holdings ranks #46 out of 384 companies in the Biotechnology industry, placing it in the top 12%.
Is PMGC Holdings' EV-to-EBIT too high?
PMGC Holdings' current EV-to-EBIT of 0.30 is 27% below median its 10-year median of 0.41. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 0.65. The Biotechnology industry median EV-to-EBIT is 12.17. PMGC Holdings' value of 0.30 is 97.5% below this industry median. Based on the distribution chart, PMGC Holdings ranks #46 out of 384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PMGC Holdings has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does PMGC Holdings' EV-to-EBIT compare to REVB and ENSC?
According to the Biotechnology industry distribution chart, PMGC Holdings ranks #46 out of 384 companies for EV-to-EBIT. This places PMGC Holdings in the top 12% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 12.17. PMGC Holdings' value of 0.30 is 97.5% below this benchmark. Historically, PMGC Holdings' own EV-to-EBIT has ranged from 0.07 to 0.65 over the past decade. While the company's 10-year median is 0.41 vs. the industry median of 12.17, PMGC Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.17, based on 384 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PMGC Holdings's current EV-to-EBIT of 0.30 is 97.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PMGC Holdings and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PMGC Holdings's current EV-to-EBIT is 0.30, which is 27% below median its own 10-year median of 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PMGC Holdings stock overvalued right now?
PMGC Holdings (ELAB) has a current EV-to-EBIT of 0.30. The current EV-to-EBIT is 0.30, which is 27% below median its 10-year median of 0.41 and 97.5% below the Biotechnology industry median of 12.17. PMGC Holdings' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For PMGC Holdings (ELAB), the current EV-to-EBIT is 0.30 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PMGC Holdings Inc IS advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
8GF Score
Get the complete analysis for ELAB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELAB has been successfully added to your 
